Tag: Cancer: Prostate
MRI-Enhanced Screening Strategy Noninferior for Prostate Cancer
MRI with targeted and standard biopsy in those with positive MRI results noninferior to standard biopsy in men with elevated PSA levels
Radioligand Therapy Slows Advanced PSMA+ Prostate Cancer
177Lu-PSMA-617 added to standard care prolonged imaging-based progression-free survival and overall survival
Race May Influence Treatment Receipt in Prostate Cancer
In high treatment benefit category, Black men less likely to receive definitive treatment than non-Black men
Adjuvant RT May Aid Men at High Risk for Death From Prostate Cancer
Adjuvant RT versus early salvage RT may lower the risk for all-cause mortality in men with adverse pathology at radical prostatectomy
Noninvasive Markers Aid Risk Assessment of Prostate Cancer
Model combining measurement of EN2 protein marker and levels of 10 genes in urine could reduce unnecessary biopsies
AHA Offers Guidance for CVD Risk in Breast, Prostate Cancer
Patients with breast, prostate cancer who are receiving hormonal therapy more likely to develop cardiovascular risk factors
Meds for Enlarged Prostate Tied to Heart Failure Risk
Risk higher for men on alpha-blockers versus 5-alpha reductase inhibitors
Threshold ID’d for Urine Test to Rule Out Prostate Cancer
In validation study, 3.7 percent of grade group ≥2 cancers missed with MyProstateScore value ≤10
Certain Prostate Drugs Tied to Risk for Parkinson Disease
Use of glycolysis-enhancing drugs terazosin, doxazosin, or alfuzosin tied to lower risk for developing Parkinson disease than use of tamsulosin
Drop in PSA Screening Linked to Increase in Metastatic Prostate Cancer
Across states, reductions in PSA screening linked to increased incidence of metastatic prostate cancer at diagnosis












